Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2022-06-15 Director's Dealing
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' and details share transactions (specifically, the grant of a pledge over shares) involving executive officers and directors (Said Darwazah, Mazen Darwazah, Mohammed 'Ali' Al-Husry) of Hikma Pharmaceuticals Plc. This type of mandatory disclosure regarding insider trading or transactions by management is specifically categorized as Director's Dealing (DIRS). The presence of the RNS Number and the reference to the London Stock Exchange confirms it is a regulatory filing, but DIRS is the most specific category for this content.
2022-06-15 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document text explicitly mentions 'HIKMA PHARMACEUTICALS PLC SHARE BUYBACK PROGRAMME' and details the 'Number of ordinary shares purchased', 'Highest price paid', 'Lowest price paid', and 'Volume weighted average price paid'. It concludes by stating, 'Following today's purchases, Hikma is pleased to announce that this share buyback programme is now complete.' This content directly relates to the company repurchasing its own shares. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2022-06-10 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is an announcement regarding a 'SHARE BUYBACK PROGRAMME' by Hikma Pharmaceuticals Plc. It details the 'Number of ordinary shares purchased', the prices paid, and the resulting change in the total number of shares in issue and total voting rights. This activity—the company purchasing its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type code is POS.
2022-06-09 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document explicitly states 'HIKMA PHARMACEUTICALS PLC SHARE BUYBACK PROGRAMME' and details the 'Number of ordinary shares purchased', 'Highest price paid', 'Lowest price paid', and provides a detailed breakdown of individual trades. This content directly relates to the company repurchasing its own shares. This matches the definition for 'Transaction in Own Shares' (Code: POS). The document is a detailed report of transactions, not just an announcement of a report, and its length (46,134 chars) suggests it is the primary filing content, not a brief RPA.
2022-06-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is an announcement regarding a 'SHARE BUYBACK PROGRAMME' by Hikma Pharmaceuticals Plc on June 7, 2022. It details the number of shares purchased, the prices paid, and the resulting change in the total number of shares in issue and total voting rights. This activity—the company purchasing its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The presence of 'RNS Number' and the nature of the announcement suggest it is a regulatory disclosure, but the specific content points overwhelmingly to the 'POS' category over the general 'RNS' fallback.
2022-06-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states 'HIKMA PHARMACEUTICALS PLC SHARE BUYBACK PROGRAMME' and details the 'Number of ordinary shares purchased', 'Highest price paid', 'Lowest price paid', and provides a detailed breakdown of individual trades executed as part of the buyback. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase).
2022-06-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.